John Yaxley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/749655/publications.pdf

Version: 2024-02-01

71 papers 2,442 citations

304368 22 h-index 214527 47 g-index

72 all docs 72 docs citations

72 times ranked 3094 citing authors

#	Article	IF	CITATIONS
1	Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet, The, 2016, 388, 1057-1066.	6.3	539
2	Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncology, The, 2018, 19, 1051-1060.	5.1	304
3	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021, 80, 682-689.	0.9	181
4	Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology, 2017, 71, 918-925.	1.6	98
5	Risk of metastatic disease on ⁶⁸ galliumâ€prostateâ€specific membrane antigen <scp>positron emission tomography</scp> / <scp>/computed tomography</scp> scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU International, 2019, 124, 401-407.	1.3	80
6	The use of ^{68Â} Gaâ€ <scp>PSMA PET CT</scp> in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU International, 2016, 118, 49-55.	1.3	79
7	Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible―on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 20-30.	3.3	79
8	68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1843-1851.	3.3	67
9	Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with ⁶⁸ Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. Journal of Urology, 2019, 201, 815-820.	0.2	64
10	The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2280-2288.	3.3	57
11	68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 477-482.	3.3	54
12	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology, 2019, 51, 463-473.	0.3	47
13	Histological comparison between predictive value of preoperative 3‶ multiparametric MRI and ⁶⁸ Gaâ€PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International, 2021, 127, 71-79.	1.3	45
14	Comparison between target magnetic resonance imaging (<scp>MRI</scp>) inâ€gantry and cognitively directed transperineal or transrectalâ€guided prostate biopsies for Prostate Imaging–Reporting and Data System (<scp>PI</scp> â€ <scp>RADS</scp>) 3–5 <scp>MRI</scp> lesions. BJU International, 2017, 120, 43-50.	1.3	42
15	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2018, 129, 377-386.	0.3	39
16	The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer and Prostatic Diseases, 2019, 22, 385-390.	2.0	39
17	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. European Urology, 2021, 80, 234-242.	0.9	35
18	Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian populationâ€based data. BJU International, 2020, 126, 18-26.	1.3	30

#	Article	IF	CITATIONS
19	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.3	29
20	Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. Journal of Magnetic Resonance Imaging, 2017, 45, 1304-1315.	1.9	26
21	MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature. World Journal of Urology, 2019, 37, 1263-1279.	1.2	25
22	Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution. Prostate Cancer and Prostatic Diseases, 2021, 24, 169-176.	2.0	24
23	Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital. World Journal of Urology, 2020, 38, 371-379.	1.2	23
24	Solitary rib lesions showing prostateâ€specific membrane antigen (PSMA) uptake in preâ€treatment staging ⁶⁸ Gaâ€PSMAâ€11 positron emission tomography scans for men with prostate cancer: benign or malignant?. BJU International, 2020, 126, 396-401.	1.3	23
25	Brachytherapy: stateâ€ofâ€theâ€art radiotherapy in prostate cancer. BJU International, 2015, 116, 80-88.	1.3	20
26	Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World Journal of Urology, 2018, 36, 15-20.	1.2	20
27	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2019, 140, 68-75.	0.3	20
28	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.3	20
29	The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 66.e1-66.e9.	0.8	20
30	Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 2017, 71, 641-647.	1.6	19
31	Findings in 1,123 Men with Preoperative ⁶⁸ Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer, Journal of Urology, 2022, 207, 573-580.	0.2	19
32	Staging of renal cell carcinoma: current progress and potential advances. Pathology, 2021, 53, 120-128.	0.3	18
33	Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.	3 . 3	18
34	Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 503-505.	0.9	16
35	A Progress Report on a Prospective Randomised Trial of Open and Robotic Prostatectomy. European Urology, 2014, 65, 512-515.	0.9	15
36	A prospective study of psychological distress after prostate cancer surgery. Psycho-Oncology, 2019, 28, 2389-2395.	1.0	15

#	Article	IF	CITATIONS
37	One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal, 2016, 10, 339.	0.3	14
38	Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation. Prostate International, 2017, 5, 149-157.	1.2	14
39	Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. Advances in Urology, 2021, 2021, 1-9.	0.6	13
40	Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy. BJU International, 2020, 126, 6-11.	1.3	12
41	Drugs for benign prostatic hypertrophy. Australian Prescriber, 2018, 41, 150-153.	0.5	11
42	Tumour-like lesions of the urinary bladder. Pathology, 2021, 53, 44-55.	0.3	11
43	Prostate artery Embolisation Assessment of Safety and feasibilitY (Pâ€ <scp>EASY</scp>): a potential alternative to longâ€term medical therapy for benign prostate hyperplasia. BJU International, 2018, 122, 27-34.	1.3	10
44	Declining use of radical prostatectomy and pelvic lymphadenectomy despite more robotics: National population data over 15 years. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e118-e124.	0.7	10
45	Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers. Prostate International, 2016, 4, 97-102.	1.2	9
46	Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study. Investigative and Clinical Urology, 2022, 63, 285.	1.0	9
47	Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?. American Journal of Surgical Pathology, 2019, 43, 1249-1252.	2.1	8
48	Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urologic Oncology: Seminars and Original Investigations, 2022, 40, 276.e1-276.e9.	0.8	8
49	Unexpected significant findings nonâ€related to prostate cancer identified using combined prostateâ€specific membrane antigen positron emission tomography/ CT and diagnostic CT scan in primary staging for prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 318-323.	0.9	6
50	Intraductal carcinoma of the prostate is not a diagnostic entity. Histopathology, 2021, 78, 342-344.	1.6	6
51	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation—A Multicenter Validation Study. European Urology Focus, 2022, 8, 1591-1598.	1.6	6
52	Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol. Contemporary Clinical Trials, 2016, 50, 16-20.	0.8	5
53	Patients Who Receive Androgen Deprivation Therapy Risk Adverse Cognitive Changes. Journal of Clinical Oncology, 2015, 33, 4314-4315.	0.8	4
54	Understanding the diagnosis of prostate cancer. Medical Journal of Australia, 2020, 213, 424-429.	0.8	4

#	Article	IF	Citations
55	Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications. European Urology Focus, 2022, 8, 1256-1269.	1.6	4
56	Review and update of benign prostatic hyperplasia in general practice., 2018, 47, 471-475.		4
57	Prognostic significance of morphological patterns of Gleason grade 5 prostatic adenocarcinoma diagnosed on needle biopsy. Pathology, 2021, 53, 199-204.	0.3	3
58	Level 1 Evidence of Better Early Urinary Continence at 3 Months Following Robot-assisted Laparoscopic Radical Prostatectomy Compared with Laparoscopic Radical Prostatectomy. Results of the LAP-01 Randomised Controlled Trial. European Urology, 2021, 79, 760-761.	0.9	3
59	Open retropubic radical prostatectomy. Translational Andrology and Urology, 2020, 9, 3025-3035.	0.6	3
60	Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?. Investigative and Clinical Urology, 2021, 62, 650.	1.0	3
61	Long-term Survival Outcomes for Men Who Provided Ejaculate Specimens for Prostate Cancer Research: Implications for Patient Management. European Urology Focus, 2015, 1, 200-206.	1.6	2
62	A novel technique for biobanking of large sections of radical prostatectomy specimens. Histopathology, 2018, 72, 481-489.	1.6	2
63	Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications. Prostate Cancer and Prostatic Diseases, 2021, 24, 398-405.	2.0	2
64	A randomised control trial of salvage radiotherapy and androgen deprivation therapy following prostatectomy: commentary on five year follow-up findings. Translational Andrology and Urology, 2016, 5, 971-973.	0.6	1
65	Assessing robot-assisted laparoscopic prostatectomy – Authors' reply. Lancet, The, 2017, 389, 800-801.	6.3	1
66	Will Favourable Functional Results with Salvage Robot-assisted Laparoscopic Radical Prostatectomy Increase the Uptake of Primary Focal Therapy for Localised Prostate Cancer?. European Urology, 2019, 76, 31-32.	0.9	1
67	Three-dimensional Elastic Augmented Reality for Robot-assisted Laparoscopic Prostatectomy: Pushing the Boundaries, but Cutting it Fine. European Urology, 2019, 76, 515-516.	0.9	1
68	The current status of renal cell carcinoma and prostate carcinoma grading. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 1057-1062.	0.7	1
69	Letter to the Editor BJUI in response to Montorsi et al .: Histological comparison between predictive value of preoperative 3â€₁ multiparametric MRI and 68 Gaâ€PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International, 2021, 127, 747-747.	1.3	0
70	Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis. Journal of Clinical Urology, 0, , 205141582210998.	0.1	0
71	Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC) Journal of Clinical Oncology, 2022, 40, 4540-4540.	0.8	0